antibody – MD Update

Special Section

Reshaping Remission

October 1, 2017 Jennifer S. Newton acute leukemia, adult leukemia, Albany, antibody, antibody therapy, baptist health, baptist health cancer, bone, bone marrow transplant, cancer, chemotherapy, Chowhan, chronic leukemia, chronic myeloid leukemia, director of medical oncology, genetic mutation, good response rate, health cancer, hematologist, IND, landscape of treatment, leukemia, line treatment, marrow, medical oncology, mutation, myeloid, myeloid leukemia, NCI, new Albany, new class, oncologist, oncology, remission, reshape remission, response rate, standard treatment, survival, survival rate, therapy, TKIs, transplant

NEW ALBANY, IND Say the word “leukemia,” and many people will immediately think of childhood cancer. But, according to the

Read more

Gastroenterology Internal Systems Special Section

Killing It Softly

November 1, 2015July 17, 2017 Jim Kelsey American society of hematology, antibody, awareness change, benign hematology patient, bone, bortezomib, cancer, cancer treatment, chemotherapy, chemotherapy cause patient, death sentence, Dr. Jessica Croley, experience nausea, hematologic malignancy, hematology, hematology patient, ibrutinib, Jessica Moss, joint practice, KentuckyOne, KentuckyOne cancer center umbrella, KentuckyOne health, KentuckyOne health hematology, lenalidomide, Louisville medical school, lymphoma, machete, major splash, medical breakthrough, misconception, Moss, myeloma, nausea, new cancer treatment, oncologist, oncology, oncology associate, oncology fellowship, oncology patient, oncology rotation, outpatient-based, pediatrics practice, physician, plasma, plasma cell, prognosis, prominent discussion topic, protein, public awareness change, scalpel, scalpel analogy, small community practice, surface of cancer cell, targeted agent, targeted drug, toxicity, toxicity of chemotherapy cause patient, traditional chemotherapy, university of Louisville medical school, visit patient

LEXINGTON “It’s like using a scalpel instead of a machete.” We are used to seeing medical breakthroughs make a major

Read more

Special Section

The Challenges of Aplastic Anemia

September 1, 2015February 1, 2017 Jill Debolt Allergy & Immunology, anemia, antibody, Aplastic, Aplastic anemia, aplastic anemia case, ATG, B cell, blood cell, bone, bone marrow, bone marrow activity, cancer, cell aplasia, cell progenitor, challenge area, challenge of Aplastic anemia, clinical practice, clinical research, complex blood disorder, decreased red blood cell count, donor, example of red cell aplasia, hematology, hematology specialist, hematopoietic, hematopoietic stem cell, hematopoietic stem cell line, hepatitis, hepatitis aplastic anemia, human B cell, immune system, immunosuppressive therapy, immunotherapy, incidence of two-to-four case, infection, KentuckyOne, KentuckyOne health, khan, Khuda, Khuda khan, Louisville Aplastic, Louisville Aplastic anemia, lung cancer, marrow, moderate aplastic anemia, new immunotherapy, note khan, oncology, oncology specialist, overwhelm infection, pancytopenia, PhD. khan, platelet, platelet count, prognosis, rare disease of the hematopoietic stem cell, red cell aplasia, red cell progenitor, scientific knowledge of the immune system, severity of aplastic anemia, specialist, spontaneous bleed, state khan, stem, stem cell transplant, suitable donor, supportive care, therapy, transfusion, transplant, treatment therapy, two-to-four case, viral hepatitis aplastic anemia, white blood cell

LOUISVILLE Aplastic anemia is a complex, relatively rare disease of the hematopoietic stem cells in the bone marrow, according to

Read more

Cancer Care Cover Story Oncology

Game Changer

July 1, 2014July 17, 2017 Jennifer S. Newton 30 to 40 % response rate, A., antibody, autoimmune, Bristol-Myers Squibb, broad clinical trial program, brown cancer center, cancer, cancer center, cancer patient, carcinoma, cell carcinoma, changer, checkpoint, checkpoint protein, Chesney, clinical trial, clinical trial center, community oncology center, CTLA-4, dose-escalation, Dr. Jason Chesney, early access, FDA, FDA approval, FDA-approved, FDA-approved drug, game changer, health care access, immune checkpoint protein, immune system, immunotherapy, imperative message, improvement, infusion, inhibitor, ipilimumab, Ipilimumab work, James Graham Brown, James Graham Brown cancer center deputy director, Jason A., Kentucky, KentuckyOne, KentuckyOne health, Louisville university, Louisville university of Louisville 's, lung, lung cancer, melanoma, melanoma patient, Merck, new class, new class of drug, Nivolumab, oncology, overall survival, patient access, PD-1, PD-1 inhibitor, PD-L1, pembrolizumab, PFK-158, phase 1/2, phase 1/2 dose-escalation trial, pretty compel, protein, renal cell carcinoma, response rate, stage 4, stage 4 cancer, stage 4 melanoma, stage 4 melanoma patient, standard FDA-approved drug, survival, survival data, survival rate, therapy, trial center, tumor, U, Yervoy®

LOUISVILLE University of Louisville’s (U of L) James Graham Brown Cancer Center Deputy Director Jason A. Chesney, MD, PhD, has

Read more

Special Section

Family Allergy & Asthma

August 1, 2012February 1, 2017 Jennifer S. Newton allergist, allergy, Allergy & Immunology, allergy practice, antibiotic, antibody, APRN, Arora, asthma, asthma 's Lexington office, asthmatic patient population, atypical infection, avoidance measure, care physician treat asthmatics, deficiency, deficiency patient, early thing, educate patient, equal mix of child, family allergy, full-time, full-time coverage, good control of symptom, guide principal, hallmark of asthma, high level of quality patient, hub office, immune deficiency, immune deficiency patient, immune system, immunotherapy, infection, inflammation of the airway, inhalant, inhalant allergy, inhaler, intradermal test, irony of medical practice, J., L., Lexington, Lexington imagine, Lexington office, Louisville, Louisville 's east end, manage partner, manage partner of family allergy, medication, monitor asthma, nurse, nurse practitioner, office site, one-in-four, one-in-four people, outdoor inhalant allergy, patient allergist, people call sinus problem, physician, potential allergic trigger, practitioner, prick skin test, primary care physician treat asthmatics, proper use of medication, provider, quality patient, Rajiv Arora, satellite office branch, service family allergy, specialty service, sub-hubs, Sublett, three-legged approach, two-thirds of people, typical antibiotic, use of provider, year-round allergy

LOUISVILLE, LEXINGTON Imagine needing to buy milk, but when you get to the grocery store they tell you the product

Read more